Research Project Process


DOCUMENTATION FOR SELECTED AWARDEES

If you are selected for the award of CF RIA research funding, the following documents must be provided prior to the start of research. In addition, no project may begin prior to the execution of a research agreement.

  • Full clinical trial protocol
  • IRB/REB approval
  • IACUC/CCAC approval

Award recipients are required to notify the CF RIA steering committee prior to the implementation of any changes to their research plan.

STATUS REPORTS

Written progress reports will be expected by the steering committee 6 months from the start of the project and then at agreed 6-month intervals.

 

PUBLICATIONS

The CF RIA program strongly encourages the award recipients to publish work carried out under an award. This includes abstract submissions to congresses and manuscripts submitted to peer-reviewed journals.

The CF RIA program expects all investigators to review the guiding principles set forth by the International Committee of Medical Journal Editors and comply with their registration and publication requirements, which can be found here: http://www.icmje.org/

RESEARCH PRESENTATION

Award recipients will be invited to present their research plan or resulting data at a research event.

TERMINATION OF SUPPORT

If the award recipient fails to comply with the terms of the agreement or the regulations under the terms of the agreement, Vertex will reserve the right to discontinue award funding.

 

PrivacyTerms of Use
© 2017 Vertex Pharmaceuticals Incorporated | VXMA-HQ-92-00065 | 10/2017
Vertex and the Vertex triangle logo are trademarks of Vertex Pharmaceuticals Incorporated
CF RIA program funding is supported by Vertex Pharmaceuticals Incorporated